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Abstract
Background: Epidemiological studies have shown that unfiltered coffee consumption is associated with a low incidence of
cancer. This study aims to identify the effects of kahweol, an antioxidant diterpene contained in unfiltered coffee, on
angiogenesis and key inflammatory molecules.
Methodology/Principal Findings: The experimental procedures included in vivo angiogenesis assays (both the chicken
and quail choriallantoic membrane assay and the angiogenesis assay with fluorescent zebrafish), the ex vivo mouse
aortic ring assay and the in vitro analysis of the effects of treatment of human endothelial cells with kahweol in cell
growth, cell viability, cell migration and zymographic assays, as well as the tube formation assay on Matrigel.
Additionally, two inflammation markers were determined, namely, the expression levels of cyclooxygenase 2 and the
levels of secreted monocyte chemoattractant protein-1. We show for the first time that kahweol is an anti-
angiogenic compound with inhibitory effects in two in vivo and one ex vivo angiogenesis models, with effects on
specific steps of the angiogenic process: endothelial cell proliferation, migration, invasion and tube formation on
Matrigel. We also demonstrate the inhibitory effect of kahweol on the endothelial cell potential to remodel
extracellular matrix by targeting two key molecules involved in the process, MMP-2 and uPA. Finally, the anti-
inflammatory potential of this compound is demonstrated by its inhibition of both COX-2 expression and MCP-1
s e c r e t i o ni ne n d o t h e l i a lc e l l s .
Conclusion/Significance: Taken together, our data indicate that, indeed, kahweol behaves as an anti-inflammatory and anti-
angiogenic compound with potential use in antitumoral therapies. These data may contribute to the explanation of the
reported antitumoral effects of kahweol, including the recent epidemiological meta-analysis showing that drinking coffee
could decrease the risk of certain cancers.
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Introduction
Many different foods contain non-nutritional components that
can have beneficial effects to the health [1]. This is the case of
coffee, which includes more than a thousand of compounds [2].
One of these is kahweol (Figure 1), an antioxidant diterpene that
remains in unfiltered coffee beverages, such as Turkish and
Scandinavian coffee [3]. Epidemiological studies associate the
consumption of unfiltered coffee with a low incidence of colon and
liver cancer [4,5]. Furthermore, its preventive effects against
oxidative stress and DNA damage are well described [6].
Angiogenesis is a hallmark of cancer, required for both cancer
progression and metastasis [7]. Mechanistically, angiogenesis is a
very complex process in which several key steps are involved [8].
In fact, when quiescent endothelial cells are activated by some
proangiogenic signal, they change their phenotype to become
highly proliferative and able to migrate, remodel the surrounding
extracellular matrix (ECM) and finally to differentiate to form new
vessels. Any of these key steps can be a potential pharmacological
target to inhibit angiogenesis and, hence, to treat angiogenesis-
dependent diseases [9].
Our group is actively involved in the search for new
modulators of angiogenesis from natural sources [10,11,12,
13,14]. In the present study, the effects of kahweol on two in
vivo and one ex vivo model of angiogenesis and on several key steps
of the process are described. They include its effects on
endothelial cell ‘‘differentiation’’ to yield tubular-like structures,
endothelial and tumor cell proliferation, apoptosis, and migra-
tion, as well as its effects on extracellular matrix remodelling
enzyme activities of matrix metalloproteinase-2 (MMP-2) and
urokinase-type plasminogen activator (uPA). We have also
investigated kahweol antiinflammatory potential through cyclo-
oxygenase-2 (COX-2) and monocyte chemoattractant protein 1
(MCP-1) modulation. Our results reinforce the potential
pharmacological interest of kahweol, as suggested by its anti-
angiogenic and anti-inflammatory effects.
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Kahweol inhibits in vivo angiogenesis
The chicken chorioallantoic membrane (CAM) assay was used
to determine the ability of kahweol to inhibit angiogenesis in vivo.
Although 50 nmol of kahweol per CAM was required to observe in
vivo inhibition of angiogenesis in 100% of treated eggs, as little as
10 nmol of kahweol was enough to induce clear inhibition of
angiogenesis in 25% of the tested eggs in the CAM assay. Figure 2
(upper lane) shows that kahweol treatment induced disorganiza-
tion and inhibition of the ingrowth of new vessels in the area
covered by the discs containing the compound. It can also be
observed that the peripheral vessels (relative to the position of the
disc) grew centrifugally, avoiding the treated area, with an overall
decrease in the vascular density.
A second experimental approach used to test the effects of
kahweol on in vivo angiogenesis was the use of a model of transgenic
zebrafish. Figure 2 (lower line) shows representative images of the
effects of 75 mM kahweol for 24 h on intersegmental vessels of 3
days-post mating larvae. The results obtained showed a decrease in
the width of some vessels and interruptions in other vessels. A
quantitative analysis of these effects revealed that 85% of 75 mM
kahweol-treated and 75% of 25 mM kahweol-treated larvae
exhibited inhibited angiogenesis (results not shown). This inhibitory
effect is unambiguously shown by video recording of blood flow. In
the supplementary material, Video S1 shows clearly a continuous
blood flow along intersegmentals vessel of control zebrafish larvae.
Incontrast,VideoS2showsthat larvae treatedwith 50 mMkahweol
for 24 h exhibited no blood flow along intersegmental vessels.
Kahweol induces non-specific cell apoptosis in quail CAM
A modified CAM assay in the quail has been adopted in our
laboratory, which makes possible to stain simultaneously endo-
thelial cells and apoptotic nuclei [15]. Figure 2 (middle line) shows
that 50 nmol kahweol induced apoptosis in a small percentage of
cells but this effect did not seem to be endothelial cell specific, since
only few apoptotic nuclei corresponded to endothelial cells.
Kahweol inhibits endothelial cell sprouting in the mouse
aortic ring assay
A third line of evidence showing the potential of kahweol to
inhibit overall angiogenesis is provided by the ex vivo model of the
mouse aortic ring assay. Figure 3 shows that under control
conditions the aortic ring was able to generate new vessel sproutings
and that the density of these sproutings increased in the presence of
the proangiogenic agent VEGF. As Figure 3 shows, kahweol
treatment inhibited endothelial cell sprouting (panel A), and this
effect was observed along treatment from day 5 to 10 (panel B).
Furthermore, a clear dose-response inhibition of microvessel
formation was observed and quantified in treatments with kahweol.
In fact, 5 mM kahweol was able to inhibit microvessel sprouting by
40%, whereas 25 mM kahweol almost completely inhibited this
angiogenic response after 10 days of treatment (panel C).
Kahweol inhibits endothelial cell proliferation
Angiogenesis involves local proliferation of endothelial cells in
response to an angiogenic stimulus. However, the desirable
endothelial cell specificityof this effect isnota commonfeature [11].
Therefore, we studied the effects of kahweol on the growth of
endothelial cells. Figure 4 shows the mean survival curves obtained
with the MTT assay in human umbilical vein endothelial cells
(HUVEC), under conditions of normal and low proliferation rates
(20% and 2% of FBS). From these curves, estimated IC50 values
were 5061 and 14767 mM for proliferative and non-proliferative
HUVEC cells, respectively. This effect on cell survival was not
endothelial cell-specific, since IC50 values for kahweol treatment of
several human tumoral cell lines were similar to those obtained for
HUVEC (results not shown).
Kahweol does not induce apoptosis on HUVEC
Cell growth is the result of the balance between their
proliferation and death rates. Therefore, it would be advisable to
Figure 2. Kahweol inhibits in vivo angiogenesis and does not
induce endothelial cell-specific apoptosis in the quail CAM
assay. A) CAM assay. Dotted circles identify the position of the methyl
cellulose discs after incubation, carried out as described in Materials and
methods. In controls, methyl cellulose discs were prepared with the
vehicle (DMSO). In treatments, methyl cellulose discs contained
50 nmol of kahweol. B) Detection of apoptosis in the quail CAM assay.
Arrows point to apoptotic cells. C) Angiogenesis assay in the zebrafish
model. The arrow points to the caudal region with narrower and
disrupted intersegmental vessels in kahweol treated zebrafish embryos.
doi:10.1371/journal.pone.0023407.g002
Figure 1. Chemical structure of kahweol.
doi:10.1371/journal.pone.0023407.g001
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However, a treatment with 25 mM kahweol was not able to induce
apoptosis in HUVEC (results not shown). As a positive control, a
treatment with 10 mM 2-methoxyestradiol was used.
Kahweol inhibits tubule formation of endothelial cells on
Matrigel
The final event during angiogenesis is the formation of a three-
dimensional network of tubes by endothelial cells. In vitro,
endothelial cells plated on Matrigel align themselves forming
cords (Figure 5, C 2, negative controls). Figure 5 shows the effect
of two different concentrations of kahweol in this assay after 6 h of
treatment. As a positive control for total inhibition, 50 mM
suramin-treatment for 6 h was used (Figure 5, C+). The kahweol
concentrations required to inhibit the differentiation of HUVEC
cells did not affect their viability (results not shown).
Kahweol inhibits HUVEC endothelial cell migration
Cell migration is a key step shared by both angiogenesis and
tumor progression. Figure 6 shows the effects of 75 mM kahweol
on endothelial cell migration, as determined by the ‘‘wound
healing’’ assay, after 8 and 24 h of treatment. Quantitative
Figure 3. Kahweol inhibits endothelial cell sprouting from aortic rings in a dose-dependent manner. Aortic ring assay was performed as
described in Materials and methods. A) Negative of photographs (x20) of aortic rings (lateral view) after 10 days of incubation in a 3D collagen gel
overlayed with complete medium in the presence of 20 mg/mL VEGF, 0.05% DMSO (the vehicle taken as a control), or kahweol at 1, 5 and 25 mM (K1,
K5, K25, respectively). Experiments were repeated at least three times. B) Microvessel time course for the different treatments mentioned in A. Data
are given as microvessel total count at different incubation times (spanning from 3 to to 10 days), and they are means6S.D. of three different
experiments. C) Microvessel total count after 10 days of incubation. Data are given as microvessel total count, and they are means6S.D. of three
different experiments. *Statistically significant (p,0.01) as compared to control values, according to a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0023407.g003
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inhibitory effect of kahweol after 8 and 24 h of treatment,
respectively.
Kahweol inhibits endothelial cell invasion
Cell invasion is another key step of angiogenesis. Data obtained
on the effects of kahweol on endothelial cell invasion (as
determined by a continuous fluorescent assay) clearly show that
kahweol induces an anti-invasive effect in HUVEC in a dose-
dependent manner (Figure 7). In fact, the rate of invasion was
inhibited a 23, 33 and 52% (as compared to the rate of invasion for
control, untreated cells) by 25, 50 and 75 mM kahweol treatments,
respectively.
Kahweol inhibits endothelial cell MMP-2 and urokinase
MMP-2 and uPA are extracellular matrix remodeling ezymes
expressed by endothelial cells and involved in angiogenesis.
Figure 8 (A) shows that kahweol inhibits HUVEC MMP-2
expression, with a clear dose response effect and complete
inhibition by 50 mM kahweol. An in situ activity assay with HT-
1080 gelatinases (Figure 8 B) shows that this is not a direct effect
on the enzyme.
Figure 8 (C) shows that kahweol-treatment induces a dose-
dependent decrease in the levels of urokinase in HUVEC
conditioned media, with an almost complete inhibition at 50 mM
kahweol.
Kahweol inhibits endothelial cell COX-2 expression and
MCP-1 secretion
COX-2 is an important pro-inflammatory protein expressed at
high levels in tumoral angiogenic vessels. Figure 9 (A and B) shows
that kahweol inhibits in a dose dependent manner the expression
of COX-2 protein by HUVEC.
Monocyte chemoattractant protein-1 (MCP-1) is a key protein
mediating inflammatory processes. Endothelial cells do express
and secrete MCP-1. Figure 9 (C) shows that kahweol treatment
also induced a dose-dependent inhibition on MCP-1 secretion by
HUVEC.
Discussion
Angiogenesis plays a key role in tumor growth, invasion and
metastasis. However, the results obtained in the clinical treatment
of cancer with approved antiangiogenic compounds show only
limited -although significant- improvement [16,17]. It should be
stressed that this first generation of antiangiogenic compounds
targets the first step of VEGF biosignaling. As we have previously
suggested, since tumor angiogenesis is very complex and involves a
number of different cell types, a multi-target approach for the anti-
angiogenic treatment of cancer could be expected to produce
better results [18]. Therefore, new multi-targeted compounds (or
combinations of them) are urgently required to be introduced in
the clinical setup. The results shown in the present study clearly
indicate that kahweol is another natural anti-angiogenic com-
pound with a wide spectrum of targets [10,11,12,19,20].
In the CAM assay, the inhibitory doses exhibited by kahweol
are similar to those of other anti-angiogenic compounds found by
us to inhibit angiogenesis in the CAM assay [10,19], and much
lower than those of other anti-angiogenic compounds [21]. The
global morphological features (including centrifugal growth of the
peripheral vessels -relative to the position of the disc-, avoiding the
treated area, with an overall decrease in the vascular density)
elicited by kahweol treatment are also in agreement with those
previously observed for other anti-angiogenic compounds. On the
other hand, the present research work shows a confirmatory
evidence of the potential of kahweol to inhibit in vivo angiogenesis,
by using another completely independent model system, namely,
that of genetically modified zebrafish. Furthermore, a third
independent approach (the mouse aortic ring assay) confirms the
high potential of kahweol to inhibit angiogenesis in a nice dose-
dependent manner.
The CAM and zebrafish in vivo assays and the ex vivo mouse
aortic ring assay clearly identify kahweol as a new anti-angiogenic
compound, but gives no information on which specific steps of
angiogenesis are targeted by this compound. To characterize an
anti-angiogenic compound, it is advisable to study its effects on the
different steps involved in angiogenesis. To get new, additional
insights on the features of kahweol as an anti-angiogenic
compound, we carried out a complete set of in vitro assays
Figure 4. Kahweol inhibits endothelial cell proliferation. Survival
curves of proliferative (squares) and non-proliferative (circles) HUVEC
endothelial cells treated with kahweol. Concentrations are represented
in logarithmic scale. Depicted data are means of values of three
independent experiments (each one with quadruplicate samples).
Standard deviation values (in all the cases lower than 20% of mean
values) are not represented for the sake of clarity.
doi:10.1371/journal.pone.0023407.g004
Figure 5. Kahweol inhibits tubule formation of endothelial cells
on Matrigel in a dose-dependent manner. Data are representative
of, at least, three independent experiments.(C2) Negative controls,
HUVEC on Matrigel with no treatment. (C +) Positive controls, HUVEC on
Matrigel treated with 50 mM suramin.
doi:10.1371/journal.pone.0023407.g005
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other compounds from natural sources, including aeroplysinin-1,
homocysteine, ursolic acid, puupehenone, hypericin, hyperforin
and aloe-emodin, among others [11,12,13,19,20,21].
Angiogenesis involves local proliferation of endothelial cells in
response to an angiogenic stimulus. In fact, several of the best
characterized anti-angiogenic compounds were initially detected
and selected for their capability to interfere with endothelial cell
growth. This is the case of the extremely selective inhibitor of
endothelial cell proliferation TNP-470, a synthetic analog of
fumagillin with enhanced anti-angiogenic properties [22,23].
Many other natural anti-angiogenic compounds inhibit endothe-
lial cell proliferation [9,10,24,25]. However, the desirable
endothelial cell specificity of this effect is not a common feature
[11]. Our data obtained with the MTT assay suggest a non-
specific cytotoxic effect of long term (3 days) treatments of both
endothelial and tumor cells with micromolar concentrations of
kahweol. Hence, kahweol seems to behave not only as a potential
anti-angiogenic compound but also as a potential anti-tumoral
compound, in agreement with previous observation from other
groups [26]. On the other hand, IC50 value for non-proliferative
HUVEC was 3-fold that obtained for proliferative HUVEC, as
expected.
Concerning the apoptosis assay, the negative effect on
endothelial (HUVEC) cells is in agreement with our results in
quail CAM. On the other hand, these data suggest that the
potential effects of kahweol on apoptosis could exhibit certain cell
specificity. Future studies in a wider range of tumor and
endothelial cell types seem warranted.
Figure 6. Kahweol inhibits endothelial cell migration. Photographs were taken on untreated (control) and 75 mM kahweol-treated HUVEC cells
at 0, 8 and 24 h after ‘‘wounding’’. Data are representative of, at least, three independent experiments. At the right, the counting of HUVEC migration
into the ‘‘wounded’’ area at 8 and 24 h after ‘‘wounding’’ is depicted. Data are given as percentages of re-occupied ‘‘wounded’’ area and they are
means6S.D. of three different experiments. White bars are control values and grey bars correspond to treatments. *Statistically significant (p,0.01)
as compared to control values, according to a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0023407.g006
Figure 7. Kahweol inhibits HUVEC endothelial cell invasion in a
dose-dependent manner. Invading controls and 25 and 75 mM
kahweol-treated HUVEC cell count values are represented by using
diamonds, squares and triangles, respectively. As negative controls, the
number of untreated invading HUVEC to wells not containing
chemoattractant was determined (crosses). Data are given as number
of invading cells and they are means of two different assays (each one
carried out in triplicate).
doi:10.1371/journal.pone.0023407.g007
Figure 8. Kahweol inhibits HUVEC MMP-2 and uPA in a dose
dependent manner. A) Gelatin zymography of MMP-2 in conditioned
media of HUVEC after treatment with different kahweol concentrations.
B) In situ determination of kahweol effects on HT-1080 gelatinases, as
determined by gelatin zymography with the presence of kahweol in the
incubation substrate buffer. C) Plasminogen zymography of HUVEC uPA
after treatment with different kahweol concentrations.
doi:10.1371/journal.pone.0023407.g008
Antiangiogenic, Antinflammatory Kahweol
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23407The final event during angiogenesis is the organization of
endothelial cells in a 3-D network of tubes. In vitro, endothelial cells
plated on Matrigel align themselves forming cords, already evident
a few hours after plating. The minimal inhibitory concentration
for kahweol in this assay of ‘‘tubule-like’’ structures formation on
Matrigel was 25 mM, in the range of concentrations at which other
known antiangiogenic compounds produce this kind of effect
[13,27]. Therefore, kahweol-treatment has another key target in
this essential step of the angiogenesis process.
Migration of endothelial cells is required for angiogenesis to
proceed. The results obtained in the ‘‘wound healing’’ assay
clearly show that 75 mM kahweol is able to inhibit endothelial cell
migration.
A key feature of endothelial cells switched to their angiogenic
phenotype is their ability to invade the surrounding space. Our
data also show that invasion is inhibited by kahweol. Since
invasion is dependent on extracellular matrix remodeling
capabilities, this inhibitory effect strongly suggested that the two
key extracellular membrane remodeling enzymes expressed by
endothelial cells, namely, MMP-2 and uPA could be other main
key targets of the pharmacological action of kahweol on
endothelial cells. Both proteases play key roles in angiogenesis,
being involved in the positive proteolytic balance required for
capillary sprout elongation and lumen formation during angio-
genesis [28,29,30,31]. Matrix metalloproteinases 2 and 9 (MMP-2,
MMP-9), commonly named gelatinases, are two key extracellular
enzymes involved in ECM remodeling, which is an essential step
required not only for angiogenesis, but also for metastasis
[32,33,34]. uPA is a serine protease that is also involved in
ECM remodeling related to angiogenesis and metastasis
[35,36,37]. Our results in the zymographic assays for gelatinase
and urokinase activities clearly showed that, in fact, kahweol was
able to inhibit the expression of both MMP-2 and uPA, identifying
them as two relevant molecular targets for kahweol.
On the other hand, the anti-oxidant nature of kahweol also
points to its potential anti-inflammatory capabilities. Our results
indicate that kahweol inhibits two key inflammatory mediators,
COX-2 and MCP-1, which are also related with angiogenesis. It
has been shown previously that kahweol exerts a suppressive effect
on COX-2 expression in macrophages [38]. Recent studies have
shown that COX-2 and MCP-1 receptor (CCR-2) induction in
HUVEC is related to increased levels of VEGF and that specific
antagonists of CCR2 decrease VEGF levels [39]. Furthermore, in
COX-2 deficient mice a decrease in VEGF, and both reduced
angiogenesis and tumor growth were observed [40]. These data
indicate that both pro-inflammatory molecules are linked to tumor
angiogenesis.
Altogether, our results demonstrate that kahweol is a potent
anti-angiogenic compound both in vitro and in vivo, targeting some
key steps shared with tumor progression, key molecules involved in
ECM remodeling (MMP-2 and uPA), and key molecules involved
in inflammation (COX-2 and MCP-1). All these effects may open
a window for the potential therapeutical application of kahweol as
an anti-angiogenic drug. In fact, recent epidemiological data show
that coffee drinking diminishes the risk of some cancers [41,42].
Furthermore, the inhibitory effects of kahweol on COX-2 and
MCP-1 reinforce the idea of kahweol being a multi-targeted
Figure 9. Kahweol inhibits HUVEC endothelial cell COX-2
expression and MCP-1 secretion in a dose-dependent manner.
A) Typical results of a Western blot assay using anti-COX-2 antibodies. B)
Quantification of the normalized relative inhibitory effect. Data are
given as percentage, taking the normalized levels of COX-2 in control
cells as 100%, and they are means6S.D. of three different assays. C)
Quantification of the amount of MCP-1 secreted by HUVEC after a 24 h
treatment in the presence of different concentrations of kahweol. Data
are given as femtograms of secreted MCP-1 per cell, and they are
means6S.D. of three different experiments. *Statistically significant
(p,0.01) as compared to control values, according to a two-tailed
Student’s t-test.
doi:10.1371/journal.pone.0023407.g009
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investigations with animal models seem warranted.
Materials and Methods
Ethics statement
All the manipulations of animals were carried out following the
rules provided by the bioethical committee of the University of
Ma ´laga and permission according to RD1201/2005 provided by
Consejerı ´a de Agricultura y Pesca (Andalusian Government). This
study is part of a research project approved by the bioethical
committee of the University of Ma ´laga.
Material and reagents
Cell culture media were purchased from Gibco (Grand Island,
NY, USA) and Cambrex (Walkersville, MD, USA). Fetal bovine
serum (FBS) was a product of Harlan-Seralab (Belton, U.K.).
Matrigel was purchased from Becton Dickinson (Bedford, MA,
USA), and Calcein-AM was from Molecular Probes (Eugene, OR,
USA). Kahweol was supplied by Sigma-Aldrich (St. Louis, MO,
USA). Stock solution (10 mg/mL) was prepared in DMSO and
stored in aliquots at –20uC. In all the assays, the vehicle (DMSO)
was at less than 1% (v/v) and controls with the vehicle alone were
carried out in parallel. Supplements and other chemicals not listed
in this section were obtained from Sigma-Aldrich. Plastic ware for
cell culture was supplied by NUNC (Roskilde, Denmark).
Cell cultures
Human umbilical vein endothelial cells (HUVEC) were isolated
by a modified collagenase treatment, as previously reported [43],
and maintained as we described elsewhere [10]. HT-1080
fibrosarcoma cells were supplied by ATCC and maintained in
culture as described by the provider. Culture media for tumor cells
were supplemented with 10% FBS, whereas culture medium for
HUVEC was supplemented with 20% FBS, with the exception of
the experiment under low proliferation rate conditions (2% FBS).
In vivo angiogenesis CAM assay
The in vivo CAM assay was carried out as described elsewhere
[21], using fertilised chick eggs, provided by Granja Santa Isabel
(Co ´rdoba, Spain). Briefly, eggs were incubated horizontally at
38uC in a humidified incubator, windowed by day 3 of incubation
and processed by day 8. Kahweol stock solution was added to a
1% solution of methylcellulose in water, and 10 mL drops of this
solution were allowed to dry on a Teflon-coated surface in a
laminar flow hood. Then, the methylcellulose discs were implanted
on the CAM, the eggs were sealed with adhesive tape and returned
to the incubator for 48 h. Negative controls were always made
with DMSO mixed with the methylcellulose. Six eggs were used
for each tested dose of kahweol. After incubation, CAMs were
examined under a stereomicroscope. The assay was scored as
positive when two independent observers reported a significant
reduction of vessels in the treated area.
In vivo angiogenesis assay with fluorescent zebrafish
Zebrafish (Danio rerio) is being used as an easy in vivo study of
angiogenesis and for the search of new modulators of angiogenesis
[44]. Furthermore, the availability of transgenic lines of zebrafish
exhibiting fluorescent blood vessels is allowing a rapid and precise
analysis of vessels, thanks to the expression of a choral green
fluorescent protein (G-RCFP) controlled by a promoter for VEGF-
R2 [45].
One day after mating, eggs were transferred to a Petri dish,
where they were treated with lye diluted to 0.5% in water for 90 s.
Then, they were washed 3 times for 3 min with water, and
maintained for 24 h at 28.5uC. After this new incubation, chorion
was retired and larvae were transferred to 96-well plates (a larva
per well) with 0.1 mL of water per well in the presence of the
indicated concentration of kahweol. After an additional 24 h
incubation at 28.5uC, effects on blood vessels were observed with a
binocular lens with filters for fluorescence and photographs were
taken from relevant images.
Video images of blood flow thru intersegmental vessels were
taken on the caudal region next to vitellus in 48 h larvae after 24 h
of treatment in the absence (control, Video S1) or presence (Video
S2) of 50 mM kahweol.
Detection of apoptosis in quail CAM
Apoptosis assays were carried out, after 24 h of incubation in the
presence of kahweol, by staining of nuclei with Hoechst as
described by us elsewhere [14].
Ex vivo mouse aortic ring assay
C57BL/6 mice (six weeks in age) were sacrificed by isofluran
inhalation according to the local ethics committee. Thoracic aorta
was carefully dissected and aortic rings were cultured in 3D
collagen gels, as previously described [46]. Cultures were
maintained at 37uC under controlled humid atmosphere (5%
CO2). The effects of kahweol, VEGF and the vehicle (DMSO) was
tested by adding them to culture media at day zero. At different
times of culture, rings were photographed under clear field
illumination by using an inverted microscope with phase contrast
Nikon Diaphot-TM (Nikon Corp., Tokyo, Japan). The angiogenic
response was quantified by microvessel counting according to
published criteria [47].
In vitro angiogenesis assays
Different in vitro assays were carried out in order to test the
specific effects of kahweol treatment on several key steps of the
angiogenic process in both endothelial and tumor cells. First of all,
the MTT cell proliferation assay was carried out to determine the
long term (after three days of incubation) cytotoxicity of kahweol
and to evaluate its IC50 value for endothelial cells, as described by
us elsewhere [10]. Subsequently, additional in vitro angiogenesis
assays were carried out both in the absence and presence of
kahweol in the range of concentrations of its IC50 value in the
MTT assay. These assays included apoptosis assay, tube formation
by endothelial cells on Matrigel, zymographic assays for the
detection of gelatinases and urokinase in conditioned media of
control and kahweol-treated cells, cell migration ‘‘wound healing’’
assay, and fluorescent cell invasion assays. All of them are
extensively described by us elsewhere [10,12]. In all these in vitro
assays, kahweol treatments were carried out under conditions
(kahweol concentration and duration of treatment) that did
produce no cytotoxic effect on cells. For zymographic assays,
conditioned media and cell extracts were obtained as previously
described by us [12]. The gelatinolytic assays were carried out in
two different ways to obtain complementary information: firstly,
cells were treated or not with the test compound and samples from
these were submitted to gelatinase zymography to detect the effects
of the kahweol treatment on the expression of gelatinase activities;
secondly, in some experiments, samples from control, untreated
HT-1080 fibrosarcoma cells were submitted to zymography and,
after electrophoresis, different concentrations of kahweol were
added to the substrate buffer to determine the potential direct
effect of kahweol on gelatinase activity. In the invasion assay,
fluorescence-labelled HUVEC cells are suspended in culture
medium in the presence of different concentrations of kahweol and
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coated with Matrigel. These inserts are added to wells containing
complete culture medium with 10% FBS as chemoattractant in
24-well fluorescence opaque plates allowing only monitoring of
fluorescence from the bottom.
Expression of COX-2
Subconfluent HUVEC cultures were stimulated with PMA
(50 ng/mL) for 4 h in the absence (controls) or presence of
different concentrations of kahweol. After incubation, cells were
washed twice with cold PBS and then lysed with cold lysis buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 1% Tritox X-100, 0.25%
sodium deoxycholate, 1 mM EDTA, 1 mM sodium orthovana-
date and 5 mg/mL of a protease inhibitors mixture). Cells were
scrapped, and maintained within a microfuge tube in ice for
15 min. Afterwards, extracts were centrifuged at 13,000 rpm for
15 min at 4uC. Supernatants were stored at 280uC until the
moment of analysis. These samples were denatured for 5 min at
95uC and submitted to SDS-PAGE. After electrophoresis, samples
were electro-transferred to nitrocellulose PROTRAN membranes,
blocked with 5% dried skimmed milk in 50 mM Tris pH 8.4,
0.9% NaCl, 0.05% Tween 20 (Tris buffered saline-Tween 20,
TBS-T), and incubated overnight in the presence of an anti-COX-
2 (at a dilution of 1:500) or anti-beta actin (at a dilution of 1:3500)
monoclonal antibodies (Santa Cruz Biotechnology and Sigma,
respectively). After three washing steps with TBS-T, a horseradish
peroxidase antibody (diluted 1:10,000 in blocking buffer) was used
as secondary antibody. After 1h of incubation at room
temperature, samples were developed using the enhanced
chemiluminescence system (GE Healthcare).
Determination of secreted MCP-1
Conditioned media from untreated and kahweol treated
HUVEC cells for 24 h were obtained. The secreted MCP-1
present in these conditioned media was quantified by using a
MCP-1 human Biotrak Easy ELISA (GE Healthcare), following
supplier’s instructions.
Statistics and image analysis
All quantitative data are expressed as means 6 standard
deviation (S.D.). Two-tailed Student’s t-test was used for
evaluations of pair of means, to establish which groups differed
from the control group. Quantitative analysis of images was
performed with the NIH Image 1.6 Program.
Supporting Information
Video S1 Blood flow thru intersegmental vessels in
control, untreated 48 h zebrafish larvae.
(AVI)
Video S2 Blood flow thru intersegmental vessels in 48 h
zebrafish larvae treated for 24 h with 50 mM kahweol.
(AVI)
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